Instagram Outage Disrupts Thousands of U.S. Users 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
 - EconoTimes)
REGULATED INFORMATION
GHENT, Belgium, 9 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received notifications of shareholdings from FMR LLC on 6 and 7 March 2018.
On 6 March 2018, FMR LLC (taking into account the holdings of its subsidiary undertakings) has notified Ablynx that it has downward crossed the 5% threshold of total voting rights of Ablynx since 1 March 2018.
On 7 March 2018, FMR LLC (taking into account the holdings of its subsidiary undertakings) has notified Ablynx that it has first downward crossed and then upward crossed the 3% threshold of voting rights (excluding the ones held through financial instruments) on respectively 5 and 6 March 2018.
FMR LLC now holds a total of 2,780,276 voting securities of Ablynx since 6 March 2018, representing 3.70% of the current 75,073,886 outstanding voting rights of Ablynx (versus 5.92% notified previously on 8 February 2018).
The latest notification contains the following information:
- Reason for the notification: acquisition or disposal of voting securities or voting rights
- Notification by: a parent undertaking or a controlling person
- Persons subject to the notification requirement: FMR LLC
- Transaction date: 6 March 2018
- Threshold that is crossed: 5%
- Denominator: 75,073,886
- Details of the notification:
| Name of select subsidiaries of FMR LLC | % of voting rights | % of voting rights held through financial instruments* | Total of both |
| FMR LLC Fidelity Management & Research Company FMR Co., Inc. | 1.69% | 0.28% | 1.97% |
| FMR LLC FIAM Holdings Corp. Fidelity Institutional Asset Management Trust Company | 1.00% | 1.00% | |
| FMR LLC FIAM Holdings Corp. FIAM LLC | 0.74% | 0.74% | |
| TOTAL | 3.43% | 0.28% | 3.70% |
* Type of financial instrument: "Right of Recall"
- Chain of controlled undertakings through which the holding is effectively being held: The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co., Inc., Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of which are entities that are subsidiaries of, and controlled by, FMR LLC. These undertakings for collective investment have granted FMR LLC discretionary power to vote the securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.
More information is available in the transparency notifications. A full version of the transparency notifications is available on Ablynx website, under the section Investors.
The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: [email protected]
Joele Frank, Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/314ed48d-abc9-4013-90f6-23b70b56d757
